Bronchiolitis epidemics in France during the SARS-CoV-2 pandemic: The 2020–2021 and 2021–2022 seasons

Vaux, Sophie; Viriot, Delphine; Forgeot, Cécile; Pontais, Isabelle; Savitch, Yann; Barondeau-Leuret, A; Smadja, Serge; Valette, Martine; Enouf, Vincent; Châtelet, Isabelle Parent du

doi:10.1016/j.idnow.2022.06.003

Cited by 14 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This resurgence of RSV infections was likely associated with reduced population-level immunity caused by the absence of infections in the previous year, combined with children’s reengagement in social activities and the relaxing of other COVID-19 public health measures . Other countries observed similar increases in RSV-associated disease, with some reports noting that it occurred without the expected proportional increases in infections and hospitalizations in older adults . The age distribution of children and adolescents hospitalized with RSV at IMPACT sites remained similar in 2021-2022 compared with pre-COVID-19 seasons, with approximately half of all patients younger than age 6 months.…”

Section: Discussionmentioning

confidence: 92%

“…21 Other countries observed similar increases in RSV-associated disease, with some reports noting that it occurred without the expected proportional increases in infections and hospitalizations in older adults. 10,[22][23][24] The age distribution of children and adolescents hospitalized with RSV at IMPACT sites remained similar in 2021-2022 compared with pre-COVID-19 seasons, with approximately half of all patients younger than age 6 months. Some studies found an increase in the proportion of older children testing positive or admitted with RSV.…”

Section: Jama Network Open | Pediatricsmentioning

confidence: 98%

See 1 more Smart Citation

Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic

Bourdeau,

Vadlamudi,

Bastien

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceRespiratory syncytial virus (RSV) is a leading cause of pediatric hospitalizations.ObjectiveTo describe the epidemiology and burden of RSV-associated hospitalizations among children and adolescents in Canadian tertiary pediatric hospitals from 2017 to 2022, including changes during the COVID-19 pandemic.Design, Setting, and ParticipantsThis cross-sectional study was conducted during 5 RSV seasons (2017-2018 to 2021-2022) at 13 pediatric tertiary care centers from the Canadian Immunization Monitoring Program Active (IMPACT) program. Hospitalized children and adolescents aged 0 to 16 years with laboratory-confirmed RSV infection were included.Main Outcomes and MeasuresThe proportion of all-cause admissions associated with RSV and counts and proportions of RSV hospitalizations with intensive care unit (ICU) admission, prolonged stay (≥7 days), and in-hospital mortality were calculated overall and by season, age group, and region. Seasonality was described using epidemic curves. RSV hospitalizations for 2021-2022 were compared with those in the prepandemic period of 2017-2018 through 2019-2020. Bonferroni corrections were applied to P values to adjust for multiple statistical comparisons.ResultsAmong 11 014 RSV-associated hospitalizations in children and adolescents (6035 hospitalizations among male patients [54.8%]; 5488 hospitalizations among patients aged &lt;6 months [49.8%]), 2594 hospitalizations (23.6%) had admission to the ICU, of which 1576 hospitalizations (60.8%) were among children aged less than 6 months. The median (IQR) hospital stay was 4 (2-6) days. The mean (SD) number of RSV-associated hospitalizations during prepandemic seasons was 2522 (88.8) hospitalizations. There were 58 hospitalizations reported in 2020-2021, followed by 3170 hospitalizations in 2021-2022. The proportion of all-cause hospitalizations associated with RSV increased from a mean of 3.2% (95% CI, 3.1%-3.3%) before the pandemic to 4.5% (95% CI, 4.3%-4.6%) in 2021-2022 (difference, 1.3 percentage points; 95% CI, 1.1-1.5 percentage points; corrected P &lt; .001). A significant increase in RSV-associated hospitalizations was found in 2021-2022 for 3 provinces (difference range, 2.5 percentage points; 95% CI, 1.4-3.6 percentage points for Quebec to 2.9 percentage points; 95% CI, 1.4-3.5 percentage points for Alberta; all corrected P &lt; .001). Age, sex, ICU admission, prolonged length of stay, and case fatality rate did not change in 2021-2022 compared with the prepandemic period. Interregional differences in RSV seasonality were accentuated in 2021-2022, with peaks for 1 province in October, 4 provinces in December, and 3 provinces in April, or May.Conclusions and RelevanceThis study found that the burden of RSV-associated hospitalizations in Canadian pediatric hospitals was substantial, particularly among infants aged less than 6 months, and RSV hospitalizations increased in 2021-2022 compared with the prepandemic period, while severity of illness remained similar. These findings suggest that RSV preventive strategies for infants aged less than 6 months would be associated with decreased RSV disease burden in children.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Jama Network Open | Pediatricsmentioning

confidence: 98%

Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic

Bourdeau,

Vadlamudi,

Bastien

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

show abstract

“…O principal agente causado da bronquiolite é o vírus sincicial respiratório humano (VSR), embora diversos outros vírus possam desempenhar um papel importante como causador dessa condição. Entre esses vírus é valido destacar o Parainfluenza Humano (HPIV), Enterovírus (EV), Adenovírus Humano (HAdV), Rinovírus (RV), vírus influenza e Metapneumovírus Humano (HMPV), Coronavírus Humano (HCoV) e Bocavirus Humano (HBov) (VAUX et al, 2022;KENMOE S, et al, 2020).…”

Section: Revisão Bibliografica Definição Epidemiologia Fatores De Ris...unclassified

Bronquiolite viral aguda

Peixoto,

Filho,

Medina

et al. 2023

Acervo Médico

View full text Add to dashboard Cite

Objetivo: Analisar as características da Bronquiolite Viral Aguda (BVA) e discutir o seu tratamento adequado. Revisão bibliográfica: A BVA é uma condição comum, especialmente em crianças com menos de dois anos. Ela se manifesta por meio de uma ampla variedade de sintomas, afetando tanto vias aéreas inferiores quanto as superiores. Entre esses sintomas, destacam-se a sibilância, hipoxemia, retrações torácicas e outros sintomas indicativos de dificuldade respiratória. Sua fisiopatologia envolve uma resposta inflamatória nas vias aéreas, resultando na produção excessiva de muco e falha na sua depuração. Considerações finais: A BVA é uma doença pulmonar frequente nos ambulatórios de pediatria. Seu diagnóstico é baseado predominantemente nas manifestações clinicas e exame físico do paciente. Quanto ao tratamento, há debate quanto ao uso de algumas medicações especificas, mas é fundamental ressaltar que o tratamento atual deve ser estritamente de suporte. Portanto, é de suma importância o conhecimento acerca da BVA para que o profissional, ao se deparar com a doença, realize o manejo, evitando complicações e resultados desfavoráveis.

show abstract

“…Since the introduction of non-pharmaceutical interventions to control COVID-19, the circulation of RSV in Europe has been limited. Surveillance data from 17 countries showed delayed RSV outbreaks in France (≥12 weeks, w), the UK, and Ireland (≥4 w) during the 2020–21 season [ 10 , 11 ]. Cases of RSV (predominantly affecting young children) in France occurred in older children compared to previous seasons.…”

Section: Introductionmentioning

confidence: 99%

Characteristics of Respiratory Syncytial Virus Infections in Children in the Post-COVID Seasons: A Northern Italy Hospital Experience

Treggiari,

Pomari,

Zavarise

et al. 2024

Viruses

View full text Add to dashboard Cite

Background: Public health measures for COVID-19 mitigation influenced the circulation of Respiratory Syncytial Virus (RSV) during the 2020–2021 winter season. In the following autumn, an unprecedented resurgence of RSV occurred. Our study monitored RSV pediatric infections one and two years after the relaxation of containment measures for the COVID-19 pandemic. Methods: We analyzed diagnostic molecular data for SARS-CoV-2, flu, and RSV infections and clinical data from children with respiratory symptoms referring to our hospital during the 2021–2022 and 2022–2023 seasons. Results: In the 2021–2022 season, the number of RSV-affected children was very high, especially for babies <1 year. The outbreak appeared in a shorter interval of time, with a high clinical severity. In the 2022–23 season, a reduced number of infected pediatric patients were detected, with a similar hospitalization rate (46% vs. 40%), and RSV accounted for 12% of the infections. Coinfections were observed in age <2 years. In RSV patients, symptoms were similar across the two seasons. Conclusions: The clinical presentation of RSV in the two post-COVID seasons suggests that the pathophysiology of the virus did not change across these two years. Further studies are needed to continuously monitor RSV to support an effective prevention strategy.

show abstract

Bronchiolitis epidemics in France during the SARS-CoV-2 pandemic: The 2020–2021 and 2021–2022 seasons

Cited by 14 publications

References 13 publications

Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic

Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic

Bronquiolite viral aguda

Characteristics of Respiratory Syncytial Virus Infections in Children in the Post-COVID Seasons: A Northern Italy Hospital Experience

Contact Info

Product

Resources

About